echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Beihai Kangcheng listed on the main board of the Hong Kong Stock Exchange

    Beihai Kangcheng listed on the main board of the Hong Kong Stock Exchange

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    Beihaikang made a global offering of 56,251,000 shares at a final issue price of HK$12.


    In this IPO, a total of seven well-known cornerstone investors participated, including RA Capital, Hudson Bay Master Fund Ltd.



    Beihai Kangcheng is a Chinese biomedical company focusing on rare diseases.


    The product pipeline of Beihai Kangcheng consists of 13 drugs, all of which have huge market potential.


    The company’s core product, CAN008, is a glycosylated CD95 Fc fusion protein for the treatment of GBM.


    "Listing on the Hong Kong Stock Exchange is a major milestone for Beihai Kangcheng.


    About Beihai Kangcheng

    Beihai Kangcheng Pharmaceutical Co.


    Beihai Kangcheng currently has a comprehensive and differentiated pipeline consisting of 13 pharmaceutical assets with huge market potential, targeting some of the most common rare diseases and rare tumor indications


    Beihai Kangcheng strategically combines global cooperation and domestic research to establish and enrich its drug portfolio, while investing in the next generation of gene therapy technology for rare disease treatment


    For more information about Beihai Kangcheng Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.